Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

Leukemia Research

Volumn 39, Issue 5, 2015, Pages 495-500

  Lanasa, Mark C ^a   Andritsos, Leslie ^b   Brown, Jennifer R ^c   Gabrilove, Janice ^d   Caligaris Cappio, Federico ^e   Ghia, Paolo ^e   Larson, Richard A ^f   Kipps, Thomas J ^g   Leblond, Veronique ^h   Milligan, Donald W ⁱ   Janssens, Ann ^j   Johnson, Amy J ^b   Heerema, Nyla A ^b   Bühler, Andreas ^k   Stilgenbauer, Stephan ^k   Devin, Jeanne ^l   Hallek, Michael ^m   Byrd, John C ^b   Grever, Michael R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k UNIVERSITY OF ULM   (Germany)

^l SANOFI   (France)

^m UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Chronic lymphocytic leukemia; Cyclin dependent kinase inhibitor; Flavopiridol; Therapy; Tumor lysis syndrome

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; ALLOPURINOL; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DEXAMETHASONE; FLAVOPIRIDOL; FLUDARABINE; RASBURICASE; RITUXIMAB; VALACICLOVIR; ANTINEOPLASTIC AGENT; FLAVONOID; PIPERIDINE DERIVATIVE; VIDARABINE;

ADULT; ANEMIA; ARTICLE; ASIAN; BLACK PERSON; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CATHETER INFECTION; CAUCASIAN; CHRONIC LYMPHATIC LEUKEMIA; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG RESPONSE; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE DELETION; HEADACHE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HUMAN; HUMAN CELL; INFECTION; INTENTION TO TREAT ANALYSIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; RASH; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR CELL DESTRUCTION; TUMOR LYSIS SYNDROME; VOMITING; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SURVIVAL ANALYSIS; TREATMENT FAILURE; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FLAVONOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PIPERIDINES; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT FAILURE; VIDARABINE;

EID: 84928089301     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.02.001     Document Type: Article

References (31)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. Engl N J Med 2005, 352:804-815.
2. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
3. Keating M.J., O'Brien S., Kontoyiannis D., et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002, 43:1755-1762.
4. Perkins J.G., Flynn J.M., Howard R.S., et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002, 94:2033-2039.
5. Tsimberidou A.M., Keating M.J. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009, 115:2824-2836.
6. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554-3561.
7. Stilgenbauer S., Zenz T., Winkler D., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009, 27:3994-4001.
8. Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1749-1755.
9. Losiewicz M.D., Carlson B.A., Kaur G., et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994, 201:589-595.
10. Kaur G., Stetler-Stevenson M., Sebers S., et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992, 84:1736-1740.
11. Kitada S., Zapata J.M., Andreeff M., et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000, 96:393-397.
12. Byrd J.C., Shinn C., Waselenko J.K., et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998, 92:3804-3816.
13. Konig A., Schwartz G.K., Mohammad R.M., et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997, 90:4307-4312.
14. Flinn I.W., Byrd J.C., Bartlett N., et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005, 29:1253-1257.
15. Lin T.S., Howard O.M., Neuberg D.S., et al. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002, 43:793-797.
16. Schwartz G.K., O'Reilly E., Ilson D., et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002, 20:2157-2170.
17. Shapiro G.I., Supko J.G., Patterson A., et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001, 7:1590-1599.
18. Byrd J.C., Lin T.S., Dalton J.T., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399-404.
19. Phelps M.A., Lin T.S., Johnson A.J., et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113:2637-2645.
20. Lin T.S., Ruppert A.S., Johnson A.J., et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009, 27:6012-6018.
21. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
22. Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127:3-11.
23. Byrd J.C., Furman R.R., Coutre S.E., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
24. Advani R.H., Buggy J.J., Sharman J.P., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31:88-94.
25. Brown J.R. Ibrutinib (PCI-32765), the first BTK (Bruton's Tyrosine Kinase) inhibitor in clinical trials. Curr Hematol Malig Rep 2013, 8:1-6.
26. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120:4684-4691.
27. Stephens D.M., Ruppert A.S., Maddocks K., et al. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res 2013, Oct;37(10):1195-1199.
28. Lin T.S., Blum K.A., Fischer D.B., et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010, 28:418-423.
29. Mahoney E., Lucas D.M., Gupta S.V., et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 2012, 120:1262-1273.
30. Ji J., Mould D.R., Blum K.A., et al. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res 2013, 19:1269-1280.
31. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.